Page 3«..2345..1020..»

Number of voting rights as of March 31, 2021

By Dr. Matthew Watson

Nicox SASociété anonyme with a registered capital of € 37,103,985

Go here to see the original:
Number of voting rights as of March 31, 2021

To Read More: Number of voting rights as of March 31, 2021
categoriaGlobal News Feed commentoComments Off on Number of voting rights as of March 31, 2021 | dataApril 4th, 2021
Read All

Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century

By Dr. Matthew Watson

WILLIAMSVILLE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it continues to be confident on the renewal of the FDA’s proposed reduced nicotine mandate that would make all cigarettes “minimally or non-addictive.” By way of support, four former U.S. Food and Drug Administration (FDA) commissioners, Robert M. Califf, M.D. MACC; Scott Gottlieb, M.D.; Peggy Hamburg, M.D.; and, Jane Henney, M.D., spoke on a recent panel and were vocal in their endorsement of the mandate to limit the amount of nicotine in cigarettes to levels already achieved by 22nd Century’s reduced nicotine content cigarettes, VLN®.

Go here to read the rest:
Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century

To Read More: Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century
categoriaGlobal News Feed commentoComments Off on Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century | dataApril 4th, 2021
Read All

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

By Dr. Matthew Watson

NANTES, France, April 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Belgian Federal Agency for Medicines and Health Products (Agence Fédérale des Médicaments et des Produits de Santé - AFMPS) and the Belgian Ethics Committee approved the Phase 1 trial evaluating its COVID-19 vaccine, named CoVepiT, on 48 healthy volunteers. First subjects are expected to be enrolled shortly.

See the rest here:
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

To Read More: OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
categoriaGlobal News Feed commentoComments Off on OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine | dataApril 4th, 2021
Read All

Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,…

By Dr. Matthew Watson

The Company is Focused on the International Expansion of Its Flagship Brand Tauri-Gum™

See original here:
Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,...

To Read More: Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,…
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,… | dataApril 4th, 2021
Read All

Autolus Therapeutics to Participate in Investor Conferences Through April

By Dr. Matthew Watson

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1’s at investor conferences through April 2021.

See the article here:
Autolus Therapeutics to Participate in Investor Conferences Through April

To Read More: Autolus Therapeutics to Participate in Investor Conferences Through April
categoriaGlobal News Feed commentoComments Off on Autolus Therapeutics to Participate in Investor Conferences Through April | dataApril 4th, 2021
Read All

Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021

By Dr. Matthew Watson

MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET.

Continued here:
Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021

To Read More: Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021
categoriaGlobal News Feed commentoComments Off on Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021 | dataApril 4th, 2021
Read All

AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary

By Dr. Matthew Watson

VANCOUVER, British Columbia, April 01, 2021 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce the signing of a definitive agreement (the “Agreement”) to sell its wholly-owned subsidiary, AAA Heidelberg Inc. (“AAA”), for cash consideration of approximately $1 million (the “Transaction”). AAA operates an 8,800 square foot indoor growing facility in London, Ontario. The closing of the Transaction is subject to customary approvals and is expected to occur in the second quarter of 2021.

The rest is here:
AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary

To Read More: AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary
categoriaGlobal News Feed commentoComments Off on AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary | dataApril 4th, 2021
Read All

Neuronetics Announces Appointment of Robert Cascella to its Board of Directors

By Dr. Matthew Watson

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Robert A. Cascella to its Board of Directors, effective immediately. Following his appointment, the Neuronetics’ Board of Directors now has eight members.

Follow this link:
Neuronetics Announces Appointment of Robert Cascella to its Board of Directors

To Read More: Neuronetics Announces Appointment of Robert Cascella to its Board of Directors
categoriaGlobal News Feed commentoComments Off on Neuronetics Announces Appointment of Robert Cascella to its Board of Directors | dataApril 4th, 2021
Read All

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

More:
GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

To Read More: GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update | dataApril 4th, 2021
Read All

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Erik Sims in connection with his employment with the Company as Controller of the Company effective on April 1, 2021. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Go here to see the original:
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

To Read More: Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | dataApril 4th, 2021
Read All

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

By Dr. Matthew Watson

Monthly information regarding the total number of voting rights and

Link:
Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

To Read More: Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021
categoriaGlobal News Feed commentoComments Off on Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 | dataApril 4th, 2021
Read All

Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.

By Dr. Matthew Watson

Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio

View original post here:
Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.

To Read More: Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.
categoriaGlobal News Feed commentoComments Off on Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc. | dataApril 4th, 2021
Read All

NKMax America Announces Corporate Name Change to NKGen Biotech

By Dr. Matthew Watson

SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that it has changed its corporate name to NKGen Biotech, Inc., which the Company believes best reflects its mission and strategic focus. The name change is effective immediately.

Go here to read the rest:
NKMax America Announces Corporate Name Change to NKGen Biotech

To Read More: NKMax America Announces Corporate Name Change to NKGen Biotech
categoriaGlobal News Feed commentoComments Off on NKMax America Announces Corporate Name Change to NKGen Biotech | dataApril 4th, 2021
Read All

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

RESEARCH TRIANGLE PARK, N.C., April 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 46,300 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more from the original source:
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataApril 4th, 2021
Read All

Valneva – Déclaration d’actions et de droits de vote – Mars 2021

By Dr. Matthew Watson

VALNEVA

Read the original here:
Valneva - Déclaration d’actions et de droits de vote – Mars 2021

To Read More: Valneva – Déclaration d’actions et de droits de vote – Mars 2021
categoriaGlobal News Feed commentoComments Off on Valneva – Déclaration d’actions et de droits de vote – Mars 2021 | dataApril 4th, 2021
Read All

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

By Dr. Matthew Watson

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.

Follow this link:
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

To Read More: ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
categoriaGlobal News Feed commentoComments Off on ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 | dataApril 4th, 2021
Read All

Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings

By Dr. Matthew Watson

Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”).  The Company has established April 12, 2021 as the record date for the Annual Meeting.

More here:
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings

To Read More: Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
categoriaGlobal News Feed commentoComments Off on Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings | dataApril 4th, 2021
Read All

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

By Dr. Matthew Watson

Montrouge, France, April 2, 2021DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

See the rest here:
DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

To Read More: DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
categoriaGlobal News Feed commentoComments Off on DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors | dataApril 4th, 2021
Read All

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

By Dr. Matthew Watson

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade

See the article here:
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

To Read More: Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
categoriaGlobal News Feed commentoComments Off on Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD | dataApril 4th, 2021
Read All

Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff

By Dr. Matthew Watson

MANCHESTER, UK, April 04, 2021 (GLOBE NEWSWIRE) -- As concern around the health risks of alcohol-based sanitiser grows, more hospitals are switching to a safer alternative – HOCL (Hypochlorous Acid), produced by SpectrumX. Hospitals have generally used alcohol-based sanitiser to prevent the spread of disease. But is the end of the line approaching for our go-to disinfectants? With other, better products on the rise, the future of alcohol sanitisers appears more and more sterile. Of course, alcohol-based solutions do their job — they kill pathogens. But they're no longer the safest or most effective option on the market.  Commonly-used alcohol sanitisers can damage skin and trigger dermatitis, eczema, and psoriasis — all of which can be a living nightmare for ever-disinfecting medical staff. They’re also toxic, posing a risk to small children who might drink them.  Just to add fuel to the fire, they’re flammable too — enough to be identified by the NHS as a fire risk when left in hot cars! With these drawbacks becoming more and more well-known, safer alternatives like HOCL are increasingly sought out by medical institutions and commercial clients. Luckily, SpectrumX – an HOCL provider based in the UK – are aiming to step into the breach, with their unique Spectricept solution. Spectricept is completely safe for human use, yet 300 times more effective than bleach at killing pathogens (including bacteria and viruses – yes, even COVID-19).  It’s the only effective formulation of HOCL ever created for use in ‘real world’ conditions —  and SpectrumX holds the license for the UK and Europe. After a year on the frontlines against COVID-19, the prospect of switching to a safer, skin-friendly disinfectant has been warmly welcomed by medical staff. Consultant Surgeon Dr Gordon Buchanan vouches for HOCL:  “My hands are my most important tool for my job. I believe we should be transitioning away from alcohol-based sanitisers in high-use environments.” Dr Gary Davies, Medical Director at Chelsea & Westminster Hospital (where Spectricept is currently used), agrees:  “At the start of the pandemic, hand washing and hand sanitisers suddenly became even more important in the drive of preventing and limiting infection, but I don’t think we necessarily imagined we would be using sanitisers so intensively and for such a long period. Over time we have seen a really significant increase in skin conditions suffered by our staff from high usage of alcohol-based sanitisers. We proactively looked for a safe and effective solution to try to prevent this from happening and have now started utilising an HOCL based product produced by SpectrumX. Feedback from staff members has been overwhelmingly positive."Whilst HOCL has important uses in the current pandemic scenario, it’s future applications have monumental potential effects for post-pandemic life. It’s clear that living in a post-pandemic world means embracing a greater level of sanitation in public  spaces, the workplace and beyond. SpectrumX are currently supporting the Medical University Hospital Innsbruck who are leading a Phase 2 clinical trial for nebulised treatment of COVID-19 patients using SPC-069. SPC-069 is a new class of HOCL-based therapy designed to treat viral bacterial and fungal infections in the lung and respiratory tract. With the benefit of successful trial data, several other potential infection treatment possibilities will be investigated. These include: pneumonia, bronchitis, asthma, flu & the common cold. With advancing  licenses for the only patent-protectable formulation of HOCL in the world, SpectrumX is set to radically alter the way humans treat infectious disease.  SpectrumX is currently raising capital prior to its 2021 listing on the London stock exchange. They intend to become a household name with their array of applications. If you would like to learn more about SpectrumX and how they will revolutionise traditional medicine please click here

Follow this link:
Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff

To Read More: Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff
categoriaGlobal News Feed commentoComments Off on Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff | dataApril 4th, 2021
Read All

Page 3«..2345..1020..»